A first derivative synchronous spectrofluorimetric method has been developed and validated for simultaneous determination of nebivolol hydrochloride (NEB) and amlodipine besylate (AML) in combined tablet dosage forms without any prior separation of components from the sample. NEB was determined at emission wavelength of 622 nm (zero-crossing wavelength point of AML). Similarly, AML was measured at 416 nm (zero-crossing wavelength point of NEB). The first derivative amplitude- concentration plots were rectilinear over the range of 0.5-2.5 μg mL-1 for NEB and 0.5-2.5 μg mL-1 for AML. The method was validated as per ICH guidelines. Limit of detection (LOD) and quantification (LOQ) are reported. The % assay in commercial formulation was found to be in the range 96.80 and 98.0 for NEB and AML respectively by the proposed method and % RSD values for precision and accuracy studies were found to be less than 2. The proposed method can be fruitfully applied for routine analysis of NEB and AML in tablets.
